Otsuka America Pharmaceutical

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Otsuka America Pharmaceutical sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 10 completed later-stage tilt top decile by trial count

Otsuka America Pharmaceutical: 10 sponsored US clinical trials, none currently recruiting.

Otsuka America Pharmaceutical sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 5 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypervolemic Hyponatremia, with 1 trials.

Top-decile sponsor footprint

Otsuka America Pharmaceutical ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 4

POCone-UBiT-IR300 Pediatric Comparison Study

NCT01623154
COMPLETED

Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia

NCT01240668
COMPLETED Phase 3

Study for the Treatment of Crohn's Disease With Adacolumn

NCT00162942
COMPLETED Phase 3

Study for the Treatment of Ulcerative Colitis With Adacolumn

NCT00102193
COMPLETED Phase 4

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

NCT00048776
COMPLETED Phase 4

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

NCT00048763
COMPLETED Phase 1

A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

NCT00002129
COMPLETED Phase 2

A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

NCT00002131
COMPLETED Phase 1

A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease

NCT00002337
COMPLETED NA

A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

NCT00002130

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 2
Phase 4 3

Therapeutic Areas

Hypervolemic Hyponatremia 1
Euvolemic Hyponatremia 1
HIV Infections 1
Crohn's Disease 1

How the Otsuka America Pharmaceutical archive is shaped

10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).

Phase mix: 5 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: Hypervolemic Hyponatremia (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Otsuka America Pharmaceutical: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Otsuka America Pharmaceutical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Otsuka America PharmaceuticalAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Otsuka America Pharmaceutical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Otsuka America Pharmaceutical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Otsuka America Pharmaceutical page

10 registered trials is a research-attention snapshot, not an endorsement of Otsuka America Pharmaceutical or any single study.

  • None of Otsuka America Pharmaceutical's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hypervolemic Hyponatremia is the condition Otsuka America Pharmaceutical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypervolemic Hyponatremia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Otsuka America Pharmaceutical pipeline card: 10 registered trials from official public datasets.Report a data error.